Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 19/20 | 0.77 |
| ▸ | FAAH | O00519 | 8/20 | 0.77 |
| ▸ | RAF1 | P04049 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390673 | 1.00 | EPHX2 (0.77) | EPHX2FAAHRAF1NPC1RAB9A | |
| SCHEMBL27004196 | 0.91 | EPHX2 (0.77) | EPHX2FAAHRAF1 | |
| SCHEMBL15624859 | 0.88 | EPHX2 (0.72) | EPHX2FAAHRAF1NPC1RAB9A | |
| SCHEMBL15624826 | 0.88 | EPHX2 (0.80) | EPHX2FAAHRAF1NPC1RAB9A | |
| SCHEMBL15624864 | 0.88 | EPHX2 (0.80) | EPHX2FAAHRAF1NPC1RAB9A | |
| SCHEMBL15271834 | 0.87 | EPHX2 (1.00) | EPHX2FAAHRAF1 | |
| SCHEMBL15612306 | 0.87 | EPHX2 (1.00) | EPHX2FAAHRAF1 | |
| SCHEMBL15612039 | 0.87 | EPHX2 (1.00) | EPHX2FAAHRAF1 | |
| SCHEMBL27004177 | 0.86 | EPHX2 (0.75) | EPHX2FAAHNPC1RAB9AEPHX1 | |
| SCHEMBL3195758 | 0.85 | EPHX2 (0.81) | EPHX2FAAHNPC1RAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | EPHX1, EPHX2, PTGER1 | EPHX2 2/4885FAAH 5/4885RAF1 1163/4885 |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | EPHX1, FAH, EPHX2 | EPHX2 3/4885FAAH 84/4885RAF1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.